US payers drop "racketeer" suit accusing Pfizer of fraudulent marketing of Lipitor
This article was originally published in Scrip
Executive Summary
A group of third-party payers in the US who paid a portion of the cost of Lipitor (atorvastatin) prescriptions for their members, have dropped their purported class action accusing Pfizer of fraudulently marketing the hypolipaemic to physicians by concealing certain side-effects and misrepresenting the drug's efficacy in some patient groups.